Pharmaceutical Executive Podcast By Pharmaceutical Executive Podcast cover art

Pharmaceutical Executive

Pharmaceutical Executive

By: Pharmaceutical Executive Podcast
Listen for free

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. Biological Sciences Science
Episodes
  • Pharmaceutical Executive Daily: Novartis Acquires Excellergy Inc.

    Pharmaceutical Executive Daily: Novartis Acquires Excellergy Inc.
    Mar 27 2026
    In today's Pharmaceutical Executive Daily, Novartis agrees to acquire Excellergy for up to $2 billion to advance a next-generation anti-IgE therapy while Otsuka moves to acquire Transcend Therapeutics in a deal valued at up to $1.225 billion, the FDA approves two first-of-their-kind therapies in Novo Nordisk's once-weekly basal insulin Awiqli and Rocket Pharmaceuticals' gene therapy Kresladi for a rare pediatric immune disease, and a new commentary argues that orphan drug manufacturers should be proactively evaluating risk contracting as a hedge against an emerging downward pricing environment.
    Show more Show less
    3 mins
  • Pharmaceutical Executive Daily: Trump Administration Misses Deadline to Nominate Permanent CDC Director

    Pharmaceutical Executive Daily: Trump Administration Misses Deadline to Nominate Permanent CDC Director
    Mar 26 2026
    In today's Pharmaceutical Executive Daily, the Trump administration misses a statutory deadline to nominate a permanent CDC director, leaving the agency in continued leadership limbo, the FDA grants accelerated approval to Denali Therapeutics' Avlayah as the first therapy designed to cross the blood-brain barrier and treat the neurological manifestations of Hunter syndrome, and a new Pharmaceutical Executive commentary breaks down what CMS's updated ASP reporting requirements mean for Part B drug manufacturers ahead of a key April deadline.
    Show more Show less
    3 mins
  • Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio

    Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
    Mar 25 2026
    In today's Pharmaceutical Executive Daily, the FDA issues a warning letter to ImmunityBio over misleading promotional claims about its bladder cancer therapy Anktiva, Merck agrees to acquire Terns Pharmaceuticals in a $6.7 billion deal while Shionogi moves to take full ownership of the Shionogi-Apnimed Sleep Science joint venture, and a new commentary examines the structural pricing problem sitting at the center of the GLP-1 access debate.
    Show more Show less
    3 mins
No reviews yet